Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Mineralys Therapeutics Inc (NASDAQ: MLYS) was $38.78 for the day, down -1.25% from the previous closing price of $39.27. In other words, the price has decreased by -$1.25 from its previous closing price. On the day, 0.9 million shares were traded. MLYS stock price reached its highest trading level at $39.523 during the session, while it also had its lowest trading level at $38.02.
Ratios:
Our analysis of MLYS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30. On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 15 ’25 when Rodman David Malcom sold 11,367 shares for $36.00 per share. The transaction valued at 409,266 led to the insider holds 81,524 shares of the business.
Rodman David Malcom bought 11,367 shares of MLYS for $409,266 on Sep 15 ’25. On Sep 04 ’25, another insider, AKKARAJU SRINIVAS, who serves as the Director of the company, bought 588,235 shares for $25.50 each. As a result, the insider paid 14,999,992 and bolstered with 588,235 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 3008152832 and an Enterprise Value of 2246011136.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.29, which has changed by 2.31453 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $40.33, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 86.71%, while the 200-Day Moving Average is calculated to be 159.34%.
Shares Statistics:
MLYS traded an average of 1.47M shares per day over the past three months and 1727890 shares per day over the past ten days. A total of 65.73M shares are outstanding, with a floating share count of 50.57M. Insiders hold about 34.81% of the company’s shares, while institutions hold 64.66% stake in the company. Shares short for MLYS as of 1756425600 were 7617115 with a Short Ratio of 5.19, compared to 1753920000 on 6996921. Therefore, it implies a Short% of Shares Outstanding of 7617115 and a Short% of Float of 15.100000999999999.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.48 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.35 and -$3.44 for the fiscal current year, implying an average EPS of -$2.72. EPS for the following year is -$2.65, with 7.0 analysts recommending between -$1.89 and -$3.43.
